Komori
COSMOS Pharmaceutical (3349) · RiskDropped

Front-loaded Demand and Subsequent Pullback Following a Consumption Tax Increase

First written in FY2020-Q2. 1 of 4 entries say "Restated". Latest entry: FY2021.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020-Q2 – FY2020-Q3MaterialisedFY20202020: 320202021: 12021
Same theme, other companies

The whole theme swung hardest in 2026: 4 of 7 companies on the "Worse" side.

32 other companies' latest entry also says "Dropped".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 120 companies compared. The sentences above are computed from all 120.
Full recordFilings, disclosures and news, newest first
  1. FY2021DroppedAnnual report
    The explanation of operating results and business risks for the fiscal year contains no explicit new reference to pre-hike demand or a post-hike decline resulting from the consumption tax increase.
  2. FY2020MaterialisedAnnual report

    「The gross profit margin was 19.7%, down 0.2 percentage point from the previous consolidated fiscal year, despite continued efforts to strengthen initiatives for value-added products and negotiate lower procurement costs. This was due, among other factors, to the decision to leave tax-inclusive prices unchanged when the consumption tax was raised in October 2019 and the sharp increase in sales of food products, which have a relatively low gross margin, in the fourth quarter.」

    The decision to leave tax-inclusive prices unchanged when the consumption tax was raised emerged in the results as a factor, along with changes in the product mix, that reduced the gross profit margin by 0.2 percentage point.
  3. FY2020-Q3RestatedAnnual report

    「During the nine-month period ended 29 February 2020, the Japanese economy became difficult to forecast because of the cooling effect of the consumption tax increase on consumer sentiment and the spread of COVID-19.」

    The Company continues to identify the impact of a consumption tax hike on consumer sentiment as a business risk.
  4. FY2020-Q2First statedAnnual report

    「In particular, consumers became more price-sensitive following the consumption tax increase in October, resulting in unexpected pre-hike demand in September and a post-hike decline in October.」

    The Company states that the consumption tax hike resulted in unexpected pre-hike demand in September before the tax increase and a subsequent decline in demand in October.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for COSMOS Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.